Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:levetiracetam
|
| gptkbp:approvalYear |
2015
|
| gptkbp:ATCCode |
N03AX14
|
| gptkbp:contraindication |
hypersensitivity to levetiracetam
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Spritam
|
| gptkbp:isSolubleIn |
gptkb:water
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
Aprecia Pharmaceuticals
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:notableFeature |
first 3D-printed drug approved by FDA
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
fatigue headache drowsiness irritability |
| gptkbp:strengthsAvailable |
500 mg
1000 mg 750 mg 250 mg |
| gptkbp:technology |
ZipDose
|
| gptkbp:usedFor |
epilepsy
myoclonic seizures primary generalized tonic-clonic seizures partial onset seizures |
| gptkbp:website |
https://www.spritam.com/
|
| gptkbp:bfsParent |
gptkb:levetiracetam
gptkb:Levetiracetam |
| gptkbp:bfsLayer |
7
|